News

PanGenetics, developing PG110, a humanised antibody to Nerve Growth Factor (NGF), has entered into an agreement with Abbott. Under the agreement Abbott will acquire the global rights to

Merck & Co. has expressed its confidence in the safety and efficacy profiles of Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin). The results of ARBITER 6 were widely predicted because

Amunix and Versartis have reported that the scientific journal Nature Biotechnology has published a comprehensive paper entitled ‘A recombinant polypeptide extends the in vivo half-life of peptides and

Bristol-Myers Squibb has announced that it will split off its holdings in Mead Johnson Nutrition. The company expects the split-off to be a tax-advantaged way to further deliver

The Medicines Company announced that the data from 13,941 patients treated in the discontinued CHAMPION Phase III program of cangrelor. CHAMPION program data were analysed after the program’s

Abbott has reported results from the ARBITER 6 – HALTS study showed patients at high cardiovascular risk had significant regression of atherosclerosis after 8 and 14 months of

Glenmark Generics (GGL) has received ANDA approval from the FDA for Ciclopirox Olamine cream, 0.77 % and will commence marketing and distribution of the product in the US

Chadha is president of Balcorp Limited, an international trade and marketing firm, which he founded in 1976 and built into a successful company with about $100 million in

BioInvent International has entered into a licence and discovery agreement with Daiichi Sankyo for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration,